The new findings will help people with SLE make informed treatment decisions.

Monday, January 29, 2024 In People with Stable Lupus, Tapering Immunosuppressant Linked to Low Flare Risk Credit: Adobe Stock In people with a form of lupus called systemic lupus erythematosus (SLE), the risk for a severe flare-up of disease was low for both individuals who tapered off long-term immunosuppressive therapy and those who remained on it, an NIAID clinical trial has found. The new study results will help people with SLE make informed decisions about tapering off treatment based on their personal circumstances and risk tolerance. The findings were published today in the journal The Lancet Rheumatology. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107